Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
3D render of Candida auris fungi
Candida auris is a multidrug-resistant fungal pathogen that causes life-threatening infections when enters the bloodstream.
iStock, BlackJack3D

Antimicrobial-Resistant C. auris Infection Rates Continue to Rise in 2023

Approximately 50 percent of Candida auris isolates resist both disinfection and multiple antibiotic drugs

American Society for Microbiology
Published:Jun 19, 2023
|2 min read
Register for free to listen to this article
Listen with Speechify

HOUSTON, TX — Candida auris, an emerging fungal pathogen resistant to many antimicrobial agents, continues to threaten US public health. Researchers at bioMérieux Inc. conducted a retrospective analysis of blood cultures positive for C. auris and found an upsurge in the detection of this pathogenic fungus between 2021 and 2023. 

The average detection rate of 0.014 percent before October 2022 (July 2020 to September 2022) rose to 0.057 percent after October 2022 (October 2022 to March 2023). They presented their findings at ASM Microbe 2023, the annual meeting of the American Society for Microbiology.

The researchers investigated changes in C. auris infection rates geographically and over time, from 2021 to 2023, by using a proprietary blood culture identification panel (BIOFIRE® BCID2) and a cloud-based surveillance network (BIOFIRE® Syndromic Trends (TREND)). The blood culture identification panel tests for 43 targets, including C. auris and the surveillance network captures anonymized patient results—greater than 100,000 positive blood cultures—in near real-time.

C. auris poses a serious health risk as approximately 50 percent of isolates resist both disinfection and multiple antibiotics. Thus, mortality rates are high when this organism becomes established in the bloodstream. First detected in the US in 2016, the C. auris infection rate increased 95 percent by 2021. The bioMérieux researchers analyzed C. auris detection rates in a US cohort from 2021 to 2023 and found a significant increase in C. auris bloodstream infections in 2023 compared with infections in previous years.

 “The study results confirm that we must continue to emphasize public health interventions under the leadership of the Centers for Disease Control and Prevention in order to meet the continuing challenge posed by antimicrobial-resistant C. auris and protect community health,” said presenting author Tristan T. Timbook, PharmD, MPH, director of Health Economics Outcomes Research, Global Medical Affairs for bioMérieux Inc. “The near real-time surveillance provided by TREND and the BIOFIRE BCID2 panel represent important tools for monitoring trends in C. auris infection.”

- This press release was originally published on The American Society for Microbiology website